Clinical Trial Update: Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluated MK-2206 in combination with lapatinib in patients with advanced or metastatic breast cancer, including HER2-positive and male breast c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Male Breast Cancer
• Stage Iiib Breast Cancer
• Stage Iiic Breast Cancer
• Unspecified Adult Solid Tumor

Drugs mentioned

• Lapatinib Ditosylate (lapatinib ditosylate)
• MK-2206 (MK-2206)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: HER2-positive Breast Cancer, Male Breast Cancer | Phase 1 | Status: COMPLETED